Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Emrusolmin (TEV-56286) in Multiple System Atrophy
jRCT2031260105Phase 2Recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of emrusolmin in multiple system atrophy (MSA), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Number of participants experiencing an adverse event and Number of participants who withdrew from the trial due to an adverse event. Started May 2026; status: recruiting.
02
Drugs
emrusolmin
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on jRCT2031260105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260105.